LOS ALTOS, Calif., January 23, 2023 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. UNCYa clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that three abstracts have been accepted for presentation at the upcoming National Kidney Foundation (NFK) Spring Clinical Meetings, being held April 11-15, 2023 in Austin, Texas.

The following data will be presented at the NFK Spring Clinical Meeting:

• Results from three UNI-494 preclinical studies that assessed the risk of drug-drug interactions (DDI) are presented in a poster entitled “In Vitro Drug Interaction Studies of UNI-494 Indicate Low Risk of Drug-Drug Interactions.” “
  
• Efficacy data from a study of UNI-494 in a bilateral renal ischemia perfusion (I/R) model is presented in a poster entitled UNI-494 Lowers Urine 2-microglobulin in Rats.
  
• The results of a study that evaluated the drug weight of different phosphate binders to bind 1 gram of phosphorus are presented in a poster titled “Binder Weight to Bind 1 Gram of Phosphate.”
  

“We continue to build on the growing body of clinical evidence supporting the therapeutic potential of our two lead programs in kidney disease and are pleased to present these positive data to an audience of leading kidney disease experts,” said Shalabh Gupta, MD, Chief Executive Officer of Unicycle Therapeutics. “Based on the recently announced results of our successful bioequivalence study of Renazorb versus Fosrenol®, we expect to submit a regulatory submission to the U.S. Food and Drug Administration (FDA) in mid-2023. These data provide further evidence of the benefits of Renasorb as a strong phosphate binder and highlight its improved product profile, which is expected to improve medication compliance and thereby improve outcomes and quality of life in patients with chronic kidney disease and hyperphosphatemia.”

“We are very encouraged that the UNI-494 data is presented as it should…